AOD-9604 + CJC-1295 + Ipamorelin · 12 mg blend
This three-name blend is listed at 12 mg total. It is a separate catalog formulation from each of its standalone ingredients. Listed specification: 12 mg.
Explore individual compounds, blends and separate-vial combinations. Compare specifications and follow each item to its reference guide.
This three-name blend is listed at 12 mg total. It is a separate catalog formulation from each of its standalone ingredients. Listed specification: 12 mg.
CJC-1295 and GHRP-2 are grouped in a 10 mg blend entry, separate from the CJC-1295/ipamorelin combinations. Listed specification: 10 mg.
This stack pairs separately listed CJC-1295 DAC and ipamorelin vials, with two CJC-1295 size options. Listed specification: 2 mg + 5 mg separate vials.
This stack pairs separately listed CJC-1295 DAC and ipamorelin vials, with two CJC-1295 size options. Listed specification: 5 mg + 5 mg separate vials.
CJC-1295 NO DAC has a standalone 5 mg listing and appears in an independently listed combination with ipamorelin. Listed specification: 5 mg.
This 10 mg blend explicitly names the no-DAC form of CJC-1295 together with ipamorelin. Listed specification: 10 mg.
Ipamorelin has 5 mg and 10 mg single-item entries and also appears in several separately indexed combinations. Listed specification: 10 mg.
Ipamorelin has 5 mg and 10 mg single-item entries and also appears in several separately indexed combinations. Listed specification: 5 mg.
Tesamorelin has 5 mg, 10 mg and 20 mg single-item entries, plus a separate combination with ipamorelin. Listed specification: 10 mg.
Tesamorelin has 5 mg, 10 mg and 20 mg single-item entries, plus a separate combination with ipamorelin. Listed specification: 20 mg.
Tesamorelin has 5 mg, 10 mg and 20 mg single-item entries, plus a separate combination with ipamorelin. Listed specification: 5 mg.
This 10 mg blend is indexed with a 5 mg tesamorelin plus 5 mg ipamorelin component label. Listed specification: 10 mg.